Opdivo Soars in Phase 3 Head and Neck Cancer Trial

Bristol-Myers Squibb’s Opdivo soared in a Phase 3 trial evaluating the drug in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

In the study, patients receiving the drug saw median overall survival of 7.5 months following chemotherapy versus 5.1 months for those taking methotrexate, docetaxel or cetuximab. Further, Opdivo yielded a one-year survival rate of 36 percent against 16.6 percent for those on the other treatments.